Anti-TREM-2 Antibody, clone 78

32160702

NA.41

TREM-2, also known as Triggering receptor expressed on myeloid cells 2 or Triggering receptor expressed on monocytes 2, and encoded by the gene Trem2/Trem2a/Trem2b/Trem2c, is a protein that forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. TREM-2 may also have a role in chronic inflammations and may stimulate production of constitutive rather than inflammatory chemokines and cytokines. TREM-2 is localized to the cell membrane and is a single pass membrane protein. TREM-2 is expressed in immune cells such as microglia and monocytes but the expression varies depending upon the exact tissue and location within the tissue. Defects in TREM-2 may be associated in humans with frontotemporal dementia, Nasu-Hakola disease, and recently an increase risk of Alzheimer′s disease.

This antibody does not cross react with mouse TREM-1 or TREM-3 (Prof. William Seaman, University of California, San Francisco.).

Recombinant protein corresponding to mouse TREM-2.

Research Category
Neuroscience
This Anti-TREM-2 Antibody, clone 78 is validated for use in western blotting, ICC, flow cytometry, inhibition & IP for the detection of TREM-2.
Immunocytochemistry Analysis: A representative lot from an independent laboratory detected TREM-2 in TRACP+ osteoclasts (Humprey, M. B., et al. (2006). J Bone Miner Res. 21(2):237-245.).

Flow Cytometry Analysis: A representative lot from an independent laboratory detected TREM-2 in RAW264.7 cells (Humprey, M. B., et al. (2006). J Bone Miner Res. 21(2):237-245.).

Immunoprecipitation Analysis: A representative lot from an independent laboratory immunoprecipitated TREM-2 from mouse macrophage lysates (Peng, Q., et al. (2010). Sci Signal. 3(122):ra38.).

Inhibition Analysis: : Pre-treatment of BV2 cells or C57BL/6 Osteoclasts with a representative lot of this antibody significantly reduces cellular activation in response to both untreated and apoptotic Neuro2A cells (Hsieh, C. L., et al. (2009). J Neurochem. (109):4:1144-1156.; Humprey, M. B., et al. (2006). J Bone Miner Res. 21(2):237-245.).
Research Sub Category
Neurodegenerative Diseases

Evaluated by Western Blotting in human spleen tissue lysate.

Western Blotting Analysis: 1 µg/mL of this antibody detected TREM-2 in 10 µg of human spleen tissue lysate.

Purified rat monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl without preservatives.
Format: Purified
Protein G Purified

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

100

rat

purified antibody

primary antibodies

78, monoclonal

human, mouse, rat

flow cytometry: suitable
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
inhibition assay: suitable
western blot: suitable

IgG1κ

NP_001259007

Q99NH8

wet ice

~25 kDa observed. Uncharacterized band(s) may be observed in some cell lysates.

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids

WGK 1